Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenyu Ding

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
National Science Review|June 22, 2026
Self-adaptive hetero-phase superlattices in TaS<sub>2</sub> via layer-resolved 1T-to-1H transformationsZhenyu Ding, Yihao Wang, Rui Li, et al.
Vaccine|April 19, 2011
Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherinZhiwei Zhao, Yaqin Yao, Zhenyu Ding, et al.
Signal Transduction and Targeted Therapy|January 21, 2021
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancerZhenyu Ding, Qing Li, Rui Zhang, et al.
Nature Medicine|August 19, 2025
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trialShaodong Hong, Qiming Wang, Ying Cheng, et al.
Cell Host & Microbe|March 25, 2026
Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinomaJianfeng Zhou, Xiaoxi Zeng, Jun Sun, et al.
Nature Medicine|April 29, 2020
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2026
Deulorlatinib (TGRX-326) in ALK gene fusion positive non-small cell lung cancer after failure of second-generation inhibitors (DRAGON): a single-arm, multicenter, phase 2 trialJie Huang, Gang Chen, Zhehai Wang, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
National Science Review|June 22, 2026
Self-adaptive hetero-phase superlattices in TaS<sub>2</sub> via layer-resolved 1T-to-1H transformationsZhenyu Ding, Yihao Wang, Rui Li, et al.
Vaccine|April 19, 2011
Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherinZhiwei Zhao, Yaqin Yao, Zhenyu Ding, et al.
Signal Transduction and Targeted Therapy|January 21, 2021
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancerZhenyu Ding, Qing Li, Rui Zhang, et al.
Nature Medicine|August 19, 2025
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trialShaodong Hong, Qiming Wang, Ying Cheng, et al.
Cell Host & Microbe|March 25, 2026
Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinomaJianfeng Zhou, Xiaoxi Zeng, Jun Sun, et al.
Nature Medicine|April 29, 2020
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2026
Deulorlatinib (TGRX-326) in ALK gene fusion positive non-small cell lung cancer after failure of second-generation inhibitors (DRAGON): a single-arm, multicenter, phase 2 trialJie Huang, Gang Chen, Zhehai Wang, et al.
Pageof 12